ImaginAb inks licensing deal with AstraZeneca

Imaging agent developer ImaginAb has signed a multiyear license agreement with AstraZeneca.

Under the terms of the nonexclusive deal, AstraZeneca will use ImaginAb's CD8 ImmunoPET in its North American and European immunotherapy clinical trials. ImaginAb will receive licensing fees, it said.

The deal follows an earlier collaboration agreement ImaginAb made in October with AstraZeneca, Pfizer, and Takeda Pharmaceutical.